Skip to content
HowShorted

Fate Therapeutics, Inc. short interest in 2025

In 2025, Fate Therapeutics, Inc.'s disclosed short interest ran from 11.15% of shares outstanding on 15 Jan 2025 to 8.73% on 31 Dec 2025, a change of -2.42 percentage points. The year's high was 14.29% on 31 Mar 2025 and its low 5.92% on 31 Oct 2025, averaging 9.42% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.00 days on 31 Mar 2025. Full history: Fate Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Fate Therapeutics, Inc. in 2025

2025 in figures

Start of year
11.15% (15 Jan 2025)
End of year
8.73% (31 Dec 2025)
Change
-2.42 pp
High
14.29% (31 Mar 2025)
Low
5.92% (31 Oct 2025)
Average
9.42%
Highest days to cover
13.00 (31 Mar 2025)
SEC filings marked
8

Every report in 2025

Fate Therapeutics, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202511.15%3.95
31 Jan 202511.30%9.51
14 Feb 202511.47%9.07
28 Feb 202511.63%3.11
14 Mar 202512.71%5.8310-K filed, results (8-K)
31 Mar 202514.29%13.00
15 Apr 202513.60%5.83
30 Apr 202511.64%6.03
15 May 202511.23%6.8210-Q filed, results (8-K)
30 May 20259.64%6.99
13 Jun 20258.30%3.69
30 Jun 20258.33%5.33
15 Jul 20258.26%6.88
31 Jul 20258.10%6.31
15 Aug 20258.15%6.0910-Q filed, results (8-K)
29 Aug 20258.37%7.16
15 Sep 20258.56%6.92
30 Sep 20256.93%3.68
15 Oct 20256.54%2.07
31 Oct 20255.92%3.09
14 Nov 20256.58%3.8010-Q filed, results (8-K)
28 Nov 20257.10%7.46
15 Dec 20257.64%7.68
31 Dec 20258.73%6.45

See also: Fate Therapeutics, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.